Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

1. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014; 65: 704-9.10.1016/j.eururo.2013.02.00223433805Search in Google Scholar

2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-17.10.1210/jc.2005-018316189261Search in Google Scholar

3. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.10.1200/JCO.2006.06.249716983113Search in Google Scholar

4. Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, Gouveia P, Leibowitz-Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24: 2972-77.10.1093/annonc/mdt39724126362Search in Google Scholar

5. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67: 124-32.10.1016/j.critrevonc.2008.01.013253665018375141Search in Google Scholar

6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.10.1056/NEJMoa04072015470213Search in Google Scholar

7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.10.1056/NEJMoa04131815470214Search in Google Scholar

8. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 2014; 5: 119-26.10.1016/j.jgo.2013.12.001435231524495703Search in Google Scholar

9. Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy. J Investig Med 2010; 58: 566-8.10.2310/JIM.0b013e3181cf9002Search in Google Scholar

10. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706-8.10.1016/j.clon.2011.04.01421602036Search in Google Scholar

11. Lund L, Borre M, Jacobsen J, Sorenson HT, Norgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. Urology 2008; 72: 1258-62.10.1016/j.urology.2007.12.018Search in Google Scholar

12. Albertsen PC, Moore DF, Shih W, Lin Y, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 1335-41.10.1200/JCO.2010.31.2330Search in Google Scholar

13. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 2011; 117: 4642-50.10.1002/cncr.26104Search in Google Scholar

14. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ. Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer. [Abstract]. J Clin Oncol 2011; 29(Suppl 7): abstr 189.10.1200/jco.2011.29.7_suppl.189Search in Google Scholar

15. Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urol Oncol 2014; 32: 36. e27-34.10.1016/j.urolonc.2013.02.015Search in Google Scholar

16. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer? Cancer 2008; 112: 1043-50.Search in Google Scholar

17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.10.1016/0895-4356(94)90129-5Search in Google Scholar

18. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7.10.1001/jama.291.20.244115161894Search in Google Scholar

19. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368-75.10.1016/j.eururo.2008.07.07818706755Search in Google Scholar

20. Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 2012; 48: 1434-42.10.1016/j.ejca.2011.10.03522119354Search in Google Scholar

21. Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 2011; 22: 118-26.10.1093/annonc/mdq30920603436Search in Google Scholar

22. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15: e404-14.10.1016/S1470-2045(14)70018-XSearch in Google Scholar

23. Donze J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: retrospective cohort study. BMJ 2013; 347: f7171.10.1136/bmj.f7171389870224342737Search in Google Scholar

24. Hernandez C, Jansa M, Vidal M, Nunez M, Bertran MJ, Garcia-Avmerich J, et al. The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital. QJM 2009; 102: 193-202.10.1093/qjmed/hcn17219147657Search in Google Scholar

25. Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM. Toxicity of initial chemotherapy in older patients with lung cancers. J Geriatr Oncol 2013; 4: 64-70.10.1016/j.jgo.2012.09.003360175423525607Search in Google Scholar

26. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Bruna-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31: 1464-70.10.1200/JCO.2012.42.989423460711Search in Google Scholar

27. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-33.10.1056/NEJMoa1405095441893124881730Search in Google Scholar

28. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48.10.1056/NEJMoa1209096368357023228172Search in Google Scholar

29. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23.10.1056/NEJMoa121375523863050Search in Google Scholar